Zacks Research Downgrades Amneal Pharmaceuticals (NASDAQ:AMRX) to Strong Sell

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks reports.

Several other equities analysts have also recently weighed in on the company. Barclays lifted their price objective on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. Leerink Partners initiated coverage on Amneal Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 target price on the stock. Oppenheimer began coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price target on the stock. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. Finally, Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $19.65 on Tuesday. The company’s 50 day moving average price is $18.40 and its two-hundred day moving average price is $15.84. Amneal Pharmaceuticals has a 12-month low of $9.56 and a 12-month high of $21.17. The firm has a market cap of $6.28 billion, a PE ratio of 40.10, a PEG ratio of 2.38 and a beta of 1.22. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts predict that Amneal Pharmaceuticals will post 0.95 earnings per share for the current year.

Insider Transactions at Amneal Pharmaceuticals

In other news, EVP Jason Daly sold 210,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 413,016 shares of company stock worth $7,216,567. Company insiders own 17.30% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at about $29,000. KBC Group NV acquired a new stake in Amneal Pharmaceuticals during the first quarter worth approximately $80,000. Strs Ohio increased its holdings in Amneal Pharmaceuticals by 158.5% in the first quarter. Strs Ohio now owns 10,600 shares of the company’s stock worth $132,000 after purchasing an additional 6,500 shares in the last quarter. Walleye Capital LLC acquired a new position in Amneal Pharmaceuticals in the first quarter valued at approximately $133,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Amneal Pharmaceuticals in the first quarter valued at approximately $136,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories.